Abstract

Metformin as First-Line Agent for Type 2 Diabetes (T2D) with Various Beneficial Aspect

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Author response: Hepatic AMPK signaling dynamic activation in response to REDOX balance are sentinel biomarkers of exercise and antioxidant intervention to improve blood glucose control
Chunwang Zhang ... Dongyun Shi
-
Chunwang Zhang, et. al.Chunwang Zhang ... Dongyun Shi
20 Sep 2022
The Genetics of Type 2 Diabetes in Youth: Where We Are and the Road Ahead
Shylaja Srinivasan ... Jennifer Todd
The Journal of Pediatrics | VOL. 247
Shylaja Srinivasan, et. al.Shylaja Srinivasan ... Jennifer Todd
01 Jun 2022
Real-world data of 12-month adjunct sodium-glucose co-transporter-2 inhibitor treatment in type 1 diabetes from the German/Austrian DPV registry: Improved HbA1c without diabetic ketoacidosis.
Peter Fasching ... Stephan Kress
Diabetes, obesity & metabolism | VOL. 24
Peter Fasching, et. al.Peter Fasching ... Stephan Kress
23 Dec 2021
New Medications for the Treatment of Diabetes.
Viral N Shah ... Satish K Garg
Diabetes technology & therapeutics | VOL. 19
Viral N Shah, et. al.Viral N Shah ... Satish K Garg
01 Feb 2017
View more papers

More From: International Journal of Endocrinology and Diabetes

Paper Title
Journal
Date
Author
-
-
International Journal of Endocrinology and Diabetes | VOL. 7
--
15 May 2024
Metformin as First-Line Agent for Type 2 Diabetes (T2D) with Various Beneficial Aspect
-
International Journal of Endocrinology and Diabetes | VOL. 7
--
15 May 2024
Type 2 Diabetes (T2D) Female Case with Clinical Efficacy of Vildaglipin, Metformin and Imeglimin
-
International Journal of Endocrinology and Diabetes | VOL. -
--
06 May 2024
-
-
International Journal of Endocrinology and Diabetes | VOL. 7
--
06 May 2024
View more papers